PD1及CARD11表达与弥漫大B细胞淋巴瘤患者远期生存的关系  

Relationship between expression of PD1 and CARD11 and long-term survival in patients with diffuse large B-cell lymphoma

作　　者：肖建波[1] 李海丽[1] 王亚秋[1] 史玉 李天一[1] XIAO Jianbo;LI Haili;WANG Yaqiu;SHI Yu;LI Tianyi(Tangchan People's Hospital,Tangshan Hebei 063000,China)

机构地区：[1]唐山市人民医院,河北唐山063000

出　　处：《中国急救复苏与灾害医学杂志》2021年第12期1401-1405,共5页China Journal of Emergency Resuscitation and Disaster Medicine

摘　　要：目的探讨程序性死亡受体1(PD1)及半胱氨酸天门冬氨酰蛋白酶(cysteine aspartyl protease,Caspasee)募集域家族成员11(caspase recruitment domain family member 11,CARD11)表达与弥漫大B细胞淋巴瘤(DLBCL)患者远期生存的关系。方法选取2012年2月-2014年12月期间唐山市人民医院收治DLBCL患者80例作为本文研究对象,免疫组化法检测淋巴结病理组织PD1和CARD11,分析二者与临床病理参数的关系,采用单因素和多因素Cox回归模型,探讨PD1和CARD11与DLBCL患者远期生存的关系。结果80例DLBCL患者中CARD11阳性为52例,阳性率为65.00%;PD1阳性为44例,阳性率为55.00%;DLBCL患者五年生存率与年龄、Ann Arbor分期、临床疗效、结外累及数目、国际预后指数(IPI)评分、B症状、病理亚型、PD1表达和CARD11表达均有统计学差异(P<0.05);Cox回归分析结果显示Ann-Arbor分期(Ⅲ~Ⅳ)(OR=1.351,95%CI:1.081~1.690)、临床疗效(无效)(OR=1.972,95%CI:1.029~3.780)、年龄(>60岁)(OR=1.473,95%CI:1.182~1.834)、PD1阳性表达(OR=2.399,95%CI:1.892~3.041)和CARD11阳性表达(OR=2.010,95%CI:1.435~2.815)是DLB⁃CL患者5年生存率的独立危险因素(P<0.05)。结论PD1和CARD11均在DLBCL淋巴结病理组织中表达,且是远期生存的独立危险因素,可作为DLBCL患者预后评估有效指标。Objective To study the relationship between expression of programmed cell death protein 1(PD1)and caspase recruitment domain family member 11(CARD11)and long-term survival in patients with diffuse large B-cell lymphoma(DLBCL).Methods 80 cases of patients with DLBCL from February 2012 to December 2014 in Tangshan People's Hospital were selected as the observation subjects.The expression levels of PD1 and CARD11 were detected by immunohistochemical method,the relationship between the PD1 and CARD11 on the clinicopathological parameters were analyzed,and univariate and multivariate Cox regression models were used to explore the relationship between PD1 and CARD11 on the long-term survival of patients with DLBCL.Results Among the 80 patients with DLBCL,52 cases were positive for CARD11,the positive rate was 65.00%;44 cases were positive for PD1,the positive rate was 55.00%.The five-year survival rate of DLBCL patients was signifi⁃cantly different with age,Ann Arbor stage,clinical efficacy,number of extranodal involvement,International Prog⁃nostic Index(IPI)score,B symptoms,pathological subtypes,PD1 expression and CARD11 expression(P<0.05).The results of Cox regression analysis showed that Ann-Arbor stage(Ⅲ~Ⅳ)(OR=1.351,95%CI:1.081~1.690),clinical efficacy(ineffective)(OR=1.972,95%CI:1.029~3.780),age(>60 years old)(OR=1.473,95%CI:1.182~1.834),PD1 positive expression(OR=2.399,95%CI:1.892~3.041)and CARD11 positive expression(OR=2.010,95%CI:1.435~2.815)were independent risk factors for 5-year survival rate in patients with DLBCL(P<0.05).Conclusion Both PD1 and CARD11 are expressed in the pathological tissues of DLBCL lymph nodes,and as in⁃dependent risk factors for long-term survival,they can be used as effective indicators for evaluating the progno⁃sis of patients with DLBCL.

关 键 词：程序性死亡受体1 Caspase募集域家族成员11 弥漫大B细胞淋巴瘤 远期生存 

分 类 号：R733.4[医药卫生—肿瘤]